Abstract
Diffuse large B-cell lymphoma (DLBCL) is heterogeneous. Gene expression profiling (GEP) has identified two principal subtypes: germinal center B cell (GCB) and activated B cell (ABC). Most DLBCL cases are distinct from Burkitt lymphoma (BL), but a subset of tumors has a GEP profile between BL and DLBCL, suggesting a spectrum. In parallel, the 2008 World Health Organization (WHO) classification included the category of B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL (BCL-U). MYC rearrangement and potential synergy with other genetic aberrations, particularly BCL2 or BCL6, so-called double hit lymphoma, have also been studied in DLBCL and gray zone lymphoma. These subsets have been associated with a poor patient outcome, with the data being strongest for MYC/BCL2 double hit lymphomas. This review summarizes the literature on the impact of MYC rearrangement, as well as MYC/BCL2 double hit, in patients with DLBCL and BCL-U. We also emphasize the evolving nature of these concepts, and outline suggestions for future studies.
Original language | English (US) |
---|---|
Pages (from-to) | 243-252 |
Number of pages | 10 |
Journal | Current hematologic malignancy reports |
Volume | 8 |
Issue number | 3 |
DOIs | |
State | Published - Sep 2013 |
Keywords
- 8q24
- Activated B cell type (ABC)
- Aggressive B cell lymphoma
- BCL2
- BCL6
- Burkitt lymphoma
- Cell of origin
- Diffuse large B cell lymphoma
- Double hit lymphoma
- Fluorescence in situ hybridization
- Gene expression profile
- Germinal center B cell type (GCB)
- Gray zone lymphoma
- High-grade B cell lymphoma
- IGH
- IGL
- Immunohistochemistry
- International prognostic index (IPI)
- Ki-67
- MYC
- Non-IG
- Prognosis
- R-CHOP
- Triple hit lymphoma
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research